Tumour necrosis factor alpha (TNF-a) is a proinflammatory cytokine that has a central role in the aetiopathogenesis of rheumatoid arthritis (RA), and may contribute to the development of hypertension. The present longitudinal study examined the effects of anti-TNFa treatment on blood pressure (BP) and vascular responses in patients with RA.
Rheumatoid arthritis (RA) is a chronic inflammatory disease, characterised by erosive symmetrical polyarthritis. It is the most common inflammatory arthritis, affecting B0.8% of the adult population. RA is also associated with increased morbidity and mortality from cardiovascular disease, which appears to be of equal frequency and severity in RA as in diabetes mellitus of similar duration. 1 This could be partially attributed to an increased prevalence of traditional cardiovascular disease risk factors, such as hypertension, dyslipidaemia and obesity. 2 In particular, the prevalence of hypertension in RA is high and its control is worse when compared with the general population. 3 Tumour necrosis factor-a (TNFa) has a central role in the aetiopathogenesis of RA, and administration of anti-TNFa biologic drugs can safely reduce disease activity and delay or reverse progressive joint damage in patients with RA. 4 Anti-TNFa therapy may also reduce cardiovascular mortality in RA 5 through currently undetermined mechanisms. In hypertension, the delicate balance between vasodilators and vasoconstrictors produced by the endothelium is upset, with disturbance in the nitric oxide pathway leading to predominance of vasoconstrictors, resulting in elevated blood pressure (BP) and endothelial dysfunction. 6 Similarly, endothelial dysfunction is also evident in RA patients, but can be improved following treatment with antiinflammatory medications (such as anti-TNFa). 7 The objective of the present study was to evaluate the effect of anti-TNFa therapy on BP measurements in RA patients compared with a control group of RA patients on stable non-biologic disease-modifying anti-rheumatic drug (DMARD) therapy and associate this with contemporary changes in microvascular and macrovascular endothelial function as well as relevant biomarkers.
Twenty-three consecutive patients with RA who were due to start clinically indicated anti-TNFa therapy and 17 RA controls on stable (for at least 3 months) non-biologic DMARD therapy were recruited from the Rheumatology outpatient clinics of the Dudley Group of Hospitals NHS Foundation Trust, United Kingdom. The exclusion criteria for both groups were previously confirmed acute coronary syndrome or established cardiovascular disease. The study had local Research Ethics Committee approval and all participants gave their written informed consent according to the Declaration of Helsinki.
Patients attended a thermoregulated (22±0.9 1C) vascular laboratory after a 12 h overnight fast for three separate visits, before starting anti-TNFa, 2 weeks and 3 months after initiation of treatment. Fifteen (65%) of the anti-TNFa patients were started on 40 mg of adalimumab, six (26%) on 50 mg of etanercept and two (9%) on infliximab with a dosage of 3 mg kg
À1
. There was no change in any of these medications or their doses during the follow-up period. Assessments at 2 weeks and 3 months were performed before the patient was about to receive the next dose of their drug. RA controls on stable non-biologic DMARD therapy were assessed at the same time points.
All patients underwent evaluation of their medical history and general demographics, examination of height, weight and body mass index. Four semi-recumbent BP measurements (including systolic BP (SBP) and diastolic BP (DBP)) were taken at minutes 24, 26, 28 and 30 after a 30 min rest period using an automated BP monitor (Datascope Accutor, Montvale, NJ, USA). The four measurements were averaged to give a single value.
Blood tests were carried out in the biochemistry laboratories at the same hospital. The disease activity score (DAS28) was also calculated on each occasion.
Concentrations of TNFa, interleukin-6 (IL-6) and IL-1b were measured from stored serum samples using FlowCytomix kits (Bender MedSystems GmbH, Vienna, Austria). Fluorescent beads were coated with antigenspecific antibodies for each of the cytokines and incubated with the sample. The assay follows the same principle as a sandwich immunoassay. Flowcytometry (Bender MedSystems GmbH) was used to differentiate bead populations by their size and fluorescent signature.
Endothelial function of the microvasculature was assessed using Laser Doppler Imaging (Moor Instruments Ltd., Devon, UK) with iontophoresis of 1% acetylcholine (endothelium-dependent) and 1% sodium-nitroprusside (endothelium-independent) (Sigma Chemical Co., St Louis, MO, USA) in 0.5 ml of saline by a single observer (AS). The technique was performed according to previously established guidelines. 8 This technique has an intra-observer co-efficient of variation for acetylcholine and sodium-nitroprusside of 6.5% and 5.9%, respectively, in our laboratory.
Assessment of macrovascular endothelial-dependent function was performed using flow-mediated dilatation with high-resolution ultrasonography of the brachial artery (Acuson Antares ultrasound system, Siemens PLC, Camberley, UK) according to previously established guidelines. 9 Following 10 minutes of rest, endothelium-independent responses were examined by administration of 500 mg sublingual glyceryl-trinitrate (GTN) tablet (Alpharma, Barnstaple, UK) while the brachial artery was imaged continuously for 5 minutes. Analysis of the brachial artery diameters were performed offline, again blindly to the patient status by AS. The intra-observer co-efficient of variation was 10.7% for flow-mediated dilatation and 11.8% for GTN assessments, respectively. For all vascular tests, endothelial function was expressed as the percentage increase in perfusion from baseline, and all analysis was carried out offline by AS who was blinded to the identity of the patient.
Statistical analysis was performed using SPSS16 (SPSS Inc, Chicago, IL, USA). Comparisons were performed by Student's t-test, Mann-Whitney U-test, and Fisher's exact test for normally distributed, non-normally distributed and categorical variables, respectively. The effect of anti-TNFa treatment on BP parameters and vascular indices (continuous variables) was tested using repeated measures analyses of variance or the Friedman test (for non-parametric variables). Sidak correction was used for pair-wise comparisons. Power calculations revealed that for detecting a 7 mm Hg SBP difference (pre and post anti-TNF therapy) with an effect size of 0.7, alpha of 0.05 and power 0.80, a total sample size of 15 patients was needed. Vascular assessments were not performed in the RA controls on stable non-biologic DMARDS as the purpose of including this group was so that control values for the BP measurements could be obtained.
RA patients receiving anti-TNFa and control patients did not differ for age (54 ± 15 vs 55 ± 10, P ¼ 0.85), body mass index (30.3±6.0 vs 30.2±7.4, P ¼ 0.93) or female gender (65 vs 71%, P ¼ 0.72). There was no significant difference between the two groups with regards to general demographics and cardiovascular risk factor prevalence. Patients starting on anti-TNFa therapy had significantly higher DAS28 score than controls (4.22±0.94 and 3.30±0.9, respectively, P ¼ 0.02). History of hypertension and antihypertensive treatment had similar prevalence in the two groups.
During follow-up, RA patients treated with antiTNFa showed a significant drop in most of their inflammatory markers including IL-6, IL-1b, CRP and DAS28 (Table 1) . A significant drop was also observed for both SBP and DBP in the 2-week and 3-month visits (Table 1 ). There were no significant differences in any of the demographic, anthropometric or cardiovascular disease risk factors between the three visits with the exception of HDL, which was significantly increased in the 2-week visit compared with baseline (Table 1) .
From the vascular measurements, only microvascular endothelium-dependent function (acetylcholine) exhibited a significant change (increased dilatation) after 2 weeks of anti-TNFa therapy compared with baseline measurements: 437 ± 247% vs 319±217%, P ¼ 0.001 (Table 1) . None of the other vascular assessments differed at follow-up (Table 1) .
In the control group of RA patients on stable nonbiologic DMARD therapy, there was no significant change in BP indices or inflammatory parameters over the time course of the study (Supplementary Table 2 ).
There was a significant difference between the change (delta) of SBP from baseline to 3-month period between the anti-TNFa and control groups (À7.7 ± 12.5 vs 4.7 ± 8.5 mm Hg, P ¼ 0.021). No significant difference in DBP change was observed among the two groups (À5.1 ± 6.7 vs 0.9 ± 11.1 mm Hg, P ¼ 0.093).
Pearson correlations did not reveal any significant associations between change in microvascular endothelial function and change in SBP. There were no significant correlations between change in SBP and DBP with change in other vascular or inflammatory parameters.
The present study reported that SBP and DBP were significantly reduced following 12 weeks of anti-TNFa therapy in patients with RA. Concurrent detailed vascular studies suggest that within this time frame, the acute effect (2 weeks) may partially be due to improved vascular function, through endothelium-dependent rather than endotheliumindependent pathways, in microvessels rather than the macrovessels. No changes in BP over time were observed in the control group, suggesting that the BP decrease in the anti-TNFa group is unlikely to be a simple conditioning effect over time.
The present study attempted to identify the potential pathways leading from TNFa signalling blockade to BP reduction. Anti-TNFa treatment resulted in reduced levels of soluble TNFa (albeit non-significant) and significantly downregulated both IL-6 and IL-1b levels. Similar results have been shown in the past both in synovial culture-based 10 and in in vivo studies. 11 These findings also explain the expected decreases in laboratory and clinical markers of inflammation (CRP and DAS 28) in the follow-up visits.
A recent post hoc analysis of the BeST trial showed that RA patients receiving anti-TNFa treatment in the form of infliximab had lower SBP and DBP than those patients who received non-biologic DMARD or prednisolone therapy after a 2-year follow-up period. 12 Interestingly, this appeared to be independent of the DAS response suggesting that the reductions in BP may have been due to a drug-specific effect.
Strengths of the present study include its longitudinal design, inclusion of a control group of RA patients with similar demographic and cardiovascular risk factor characteristics, and the simultaneous biochemical and vascular assessments of endothelium-dependent and endothelium-independent dilatation in the microvasculature and the macrovasculature. Limitations of the present study include the short follow-up period and small sample size limiting the ability to adjust for potential confounders and lack of randomisation. However, treatment decision was made by the rheumatologist based on clinical need and it was considered unethical to withhold potentially beneficial medication from patients.
In summary, this study shows a significant reduction in both SBP and DBP measurements as early as 2 weeks and sustained up to 12 weeks after commencement of anti-TNFa therapy in patients with active RA. The reduction in BP parallels a reduction in disease activity and a potential shortterm improvement in microvascular endotheliumdependent dilatation. The causality of this observation cannot be determined based on the findings of the present study and future mechanistic studies are needed to confirm these findings. What is known about this topic K Prevalence of hypertension in rheumatoid arthritis is high. K Control of hypertension is far from adequate in rheumatoid arthritis. K Anti-inflammatory treatment with tumour necrosis factor-a inhibitors may reduce blood pressure in these patients What this study adds K A reduction in systemic inflammation after 3 months of treatment with tumour necrosis factor-a inhibitor contributes to improvements in blood pressure as well as microvascular endothelial-dependent function. K The reduction in blood pressure in response to treatment is likely to be mediated by the improvement in microvascular endothelial-dependent function.
